Patents by Inventor Ana Fernandez Casares

Ana Fernandez Casares has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID FORMS AND COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF
    Publication number: 20240101580
    Abstract: Described herein are crystalline forms of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid. In some embodiments, the crystalline forms are formulated for treating a subject in need thereof with a bacterial infection.
    Type: Application
    Filed: September 27, 2023
    Publication date: March 28, 2024
    Inventors: Christopher J. BURNS, Daniel C. PEVEAR, Luigi XERRI, Timothy HENKEL, Daniel MCGARRY, Lawrence ROSEN, Gerald BRENNER, Jean-Baptiste ARLIN, Ana FERNANDEZ CASARES
  • Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
    Patent number: 11820784
    Abstract: Described herein are crystalline forms of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid. In some embodiments, the crystalline forms are formulated for treating a subject in need thereof with a bacterial infection.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: November 21, 2023
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Daniel C. Pevear, Luigi Xerri, Timothy Henkel, Daniel McGarry, Lawrence Rosen, Gerald Brenner, Jean-Baptiste Arlin, Ana Fernandez Casares
  • SOLID FORMS AND COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF
    Publication number: 20220002322
    Abstract: Described herein are crystalline forms of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid. In some embodiments, the crystalline forms are formulated for treating a subject in need thereof with a bacterial infection.
    Type: Application
    Filed: June 21, 2021
    Publication date: January 6, 2022
    Inventors: Christopher J. BURNS, Daniel C. PEVEAR, Luigi XERRI, Timothy HENKEL, Daniel MCGARRY, Lawrence ROSEN, Gerald BRENNER, Jean-Baptiste ARLIN, Ana FERNANDEZ CASARES
  • Edaravone salt
    Patent number: 11117868
    Abstract: The invention relates to a salt of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone), wherein the salt is 3-methyl-1-phenyl-2-pyrazolin-5-one napadisylate or 3-methyl-1-phenyl-2-pyrazolin-5-one hemi-napadisylate. These napadisylate salts of edaravone are easy to manufacture and dissolve more rapidly in water than the free edaravone base. In addition, the edaravone salts of the present invention are very stable and easy to handle. The invention also relates to a pharmaceutical composition comprising the aforementioned edaravone salt and to a method of preparing such edaravone salt.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: September 14, 2021
    Assignee: TREEWAY TW001 B.V.
    Inventors: Ana Fernandez Casares, Ronald Van Der Geest, Sytske Hyke Moolenaar
  • Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
    Patent number: 11091505
    Abstract: Described herein are crystalline forms of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid. In some embodiments, the crystalline forms are formulated for treating a subject in need thereof with a bacterial infection.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: August 17, 2021
    Assignee: VenatoRx Pharmaceuticals, Inc.
    Inventors: Christopher J. Burns, Daniel C. Pevear, Luigi Xerri, Timothy Henkel, Daniel McGarry, Lawrence Rosen, Gerald Brenner, Jean-Baptiste Arlin, Ana Fernandez Casares
  • EDARAVONE SALT
    Publication number: 20200308120
    Abstract: The invention relates to a salt of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone), wherein the salt is 3-methyl-1-phenyl-2-pyrazolin-5-one napadisylate or 3-methyl-1-phenyl-2-pyrazolin-5-one hemi-napadisylate. These napadisylate salts of edaravone are easy to manufacture and dissolve more rapidly in water than the free edaravone base. In addition, the edaravone salts of the present invention are very stable and easy to handle. The invention also relates to a pharmaceutical composition comprising the aforementioned edaravone salt and to a method of preparing such edaravone salt.
    Type: Application
    Filed: April 10, 2020
    Publication date: October 1, 2020
    Applicant: Treeway TW001 B.V.
    Inventors: Ana Fernandez Casares, Ronald Van Der Geest, Sytske Hyke Moolenaar
  • SOLID FORMS AND COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF
    Publication number: 20200010485
    Abstract: Described herein are crystalline forms of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid. In some embodiments, the crystalline forms are formulated for treating a subject in need thereof with a bacterial infection.
    Type: Application
    Filed: March 5, 2018
    Publication date: January 9, 2020
    Inventors: Christopher J. BURNS, Daniel C. PEVEAR, Luigi XERRI, Timothy HENKEL, Daniel MCGARRY, Lawrence ROSEN, Gerald BRENNER, Jean-Baptiste ARLIN, Ana FERNANDEZ CASARES
  • Polymorphic forms of minocycline base and processes for their preparation
    Patent number: 10351515
    Abstract: The present invention concerns new forms of crystalline minocycline base. In particular, two new crystalline polymorphic forms, designated Form IV and Form V of minocycline base are provided. These are characterized by XRD, FTIR and TGA. Processes for preparing the new polymorphic forms and their use in pharmaceutical compositions are also provided. Form IV and form V are prepared by dissolving and/or suspending minocycline base in an organic solvent followed by crystallization.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: July 16, 2019
    Assignee: Hovione Scientia Limited
    Inventors: Zita Mendes, Constanca Cacela, Gloria Ten Figas, Ana Fernandez Casares
  • Polymorphic forms of minocycline base and processes for their preparation
    Patent number: 10351516
    Abstract: Described are new forms of crystalline minocycline base. In particular, two new crystalline polymorphic forms, designated Form IV and Form V of minocycline base are provided. These are characterized by XRD, FTIR and TGA. Processes for preparing the new polymorphic forms and their use in pharmaceutical compositions are also provided. Form IV and Form V are prepared by dissolving and/or suspending minocycline base in an organic solvent followed by crystallization.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: July 16, 2019
    Assignee: Hovione Scientia Limited
    Inventors: Zita Mendes, Constanca Cacela, Gloria Ten Figas, Ana Fernandez Casares
  • Ibrutinib solid forms and production process therefor
    Patent number: 10280173
    Abstract: Provided are ibrutinib polymorphs, e.g., crystalline ibrutinib Forms III, IV, V, VI, VII, VIII and Form IX and processes for producing these crystalline forms, stable amorphous ibrutinib and processes for preparing stable amorphous ibrutinib, pharmaceutical compositions comprising these forms and methods of using these crystalline and amorphous forms.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: May 7, 2019
    Assignee: WAVELENGTH ENTERPRISES LTD
    Inventors: Itai Adin, Sonia Krivonos, Yevgeny Rozenblat, Alex Weisman, Ana Fernandez Casares, Gloria Ten Figas, Revital Ben-Daniel
  • Polymorphic Forms of Minocycline Base and Processes For Their Preparation
    Publication number: 20180339962
    Abstract: Described are new forms of crystalline minocycline base. In particular, two new crystalline polymorphic forms, designated Form IV and Form V of minocycline base are provided. These are characterized by XRD, FTIR and TGA. Processes for preparing the new polymorphic forms and their use in pharmaceutical compositions are also provided. Form IV and Form V are prepared by dissolving and/or suspending minocycline base in an organic solvent followed by crystallization.
    Type: Application
    Filed: July 23, 2018
    Publication date: November 29, 2018
    Applicant: Hovione Scientia Limited
    Inventors: Zita Mendes, Constanca Cacela, Gloria Ten Figas, Ana Fernandez Casares
  • CRYSTALLINE SOLID FORMS OF THE ACETATE SALT OF (1S,3S,4R)-4-((3AS,4R,5S,7AS)-4-(AMINOMETHYL)-7A-METHYL-1-METHYLENEOCTAHYDRO-1H-INDEN-5-YL)-3-(HYDROXYMETHYL)-4-METHYLCYCLOHEXANOL
    Publication number: 20180290964
    Abstract: The present invention is generally directed to methods of using novel crystalline forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol and pharmaceutical compositions comprising same.
    Type: Application
    Filed: June 14, 2018
    Publication date: October 11, 2018
    Inventors: Lloyd F. Mackenzie, Jeffery R. Raymond, Curtis Harwig, Ana Fernandez Casares
  • IBRUTINIB SOLID FORMS AND PRODUCTION PROCESS THEREFOR
    Publication number: 20180251463
    Abstract: Provided are ibrutinib polymorphs, e.g., crystalline ibrutinib Forms III, IV, V, VI, VII, VIII and Form IX and processes for producing these crystalline forms, stable amorphous ibrutinib and processes for preparing stable amorphous ibrutinib, pharmaceutical compositions comprising these forms and methods of using these crystalline and amorphous forms.
    Type: Application
    Filed: December 22, 2017
    Publication date: September 6, 2018
    Applicant: WAVELENGTH ENTERPRISES LTD.
    Inventors: Itai ADIN, Sonia KRIVONOS, Yevgeny ROZENBLAT, Alex WEISMAN, Ana FERNANDEZ CASARES, Gloria TEN FIGAS, Revital BEN-DANIEL
  • Crystalline solid forms of the acetate salt of (1S,3S,4R)-4-((3AS,4R,5S,7AS)-4-(aminomethyl)-7A-methyl-1-methyleneoctahydro-1H-inden-5-YL)-3- (hydroxymethyl)-4-methylcyclohexanol
    Patent number: 10065920
    Abstract: The present invention is generally directed to novel crystalline forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol and processes for their preparation.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: September 4, 2018
    Assignee: Aquinox Pharmaceuticals (Canada) Inc.
    Inventors: Lloyd F. Mackenzie, Jeffery R. Raymond, Curtis Harwig, Ana Fernandez Casares
  • CRYSTALLINE SOLID FORMS OF THE ACETATE SALT OF (1S,3S,4R)-4-((3AS,4R,5S,7AS)-4-(AMINOMETHYL)-7A-METHYL-1-METHYLENEOCTAHYDRO-1H-INDEN-5-YL)-3-(HYDROXYMETHYL)-4-METHYLCYCLOHEXANOL
    Publication number: 20180155273
    Abstract: The present invention is generally directed to novel crystalline forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol and processes for their preparation.
    Type: Application
    Filed: January 31, 2018
    Publication date: June 7, 2018
    Inventors: Lloyd F. Mackenzie, Jeffery R. Raymond, Curtis Harwig, Ana Fernandez Casares
  • Crystalline solid forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol
    Patent number: 9944590
    Abstract: The present invention is generally directed to novel crystalline forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol and processes for their preparation.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: April 17, 2018
    Assignee: Aquinox Pharmaceuticals (Canada) Inc.
    Inventors: Lloyd F. Mackenzie, Jeffery R. Raymond, Curtis Harwig, Ana Fernandez Casares
  • New Polymorphic Forms of Minocycline Base and Processes for their Preparation
    Publication number: 20180029977
    Abstract: The present invention concerns new forms of crystalline minocycline base. In particular, two new crystalline polymorphic forms, designated Form IV and Form V of minocycline base are provided. These are characterized by XRD, FTIR and TGA. Processes for preparing the new polymorphic forms and their use in pharmaceutical compositions are also provided. Form IV and form V are prepared by dissolving and/or suspending minocycline base in an organic solvent followed by crystallization.
    Type: Application
    Filed: February 12, 2016
    Publication date: February 1, 2018
    Applicant: Hovione Scientia Limited
    Inventors: Zita Mendes, Constanca Cacela, Gloria Ten Figas, Ana Fernandez Casares
  • CRYSTALLINE SOLID FORMS OF THE ACETATE SALT OF (1S,3S,4R)-4-((3AS,4R,5S,7AS)-4-(AMINOMETHYL)-7A-METHYL-1-METHYLENEOCTAHYDRO-1H-INDEN-5-YL)-3-(HYDROXYMETHYL)-4-METHYLCYCLOHEXANOL
    Publication number: 20160376222
    Abstract: The present invention is generally directed to novel crystalline forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol and processes for their preparation.
    Type: Application
    Filed: June 23, 2016
    Publication date: December 29, 2016
    Inventors: Lloyd F. Mackenzie, Jeffery R. Raymond, Curtis Harwig, Ana Fernandez Casares